ADVOCACY WIN: Long Delayed Funding Notification for NIH-Funded HIV Clinical Trials Networks is Released

November 20, 2026 – The Save HIV Funding Campaign welcomes today’s release of the long-overdue Notice of Funding Opportunities (NOFOs) for NIH’s four HIV Clinical Trials Networks. We celebrate the continued ability of the Trials Networks to advance their critical work to end the HIV epidemic. This is an important advocacy victory and a testament to the power of sustained community mobilization and collective action.

For months, the Save HIV Funding Campaign and its partners have pressed the administration and Congress to address delays that threatened the continuity of these critical research networks and the studies, researchers, and communities that depend on them. A day before the release of the NOFOs, advocates and allies in business brought this urgent issue directly to NIH Director Jay Bhattacharya during a discussion on the future of HIV research, underscoring the growing pressure for action.

Today’s announcement represents an important step toward protecting the future of HIV clinical research and the infrastructure that has driven decades of scientific progress. We thank the advocates, community organizations, researchers, and congressional champions who helped make this possible. Our message was clear: HIV research cannot afford to wait, and our collective advocacy made a difference.

We will continue to monitor the process to ensure these funding opportunities translate into timely awards and uninterrupted support for the HIV Clinical Trials Networks. As we continue to review the announcement, we will also fight back against anything reflecting dangerous anti-science ideologies including unnecessarily complicating collaboration with international researchers. 

“We are delighted to have helped save the HIV networks from destruction! As someone who has worked in HIV research for 40 years because of losing so many loved ones, I’m extremely proud of the HIV advocacy community that initially helped to build the clinical trials networks. Many of the same people as well as many new HIV research  advocates have really helped to ensure the continued existence of the NIAID networks that are responsible for so many lifesaving accomplishments! Onward to an HIV vaccine and cure!” Lynda Dee, Executive Director, AIDS Action Baltimore

“Millions of people living with HIV are alive because of research conducted over the past 40 years by the NIH-funded clinical trials networks. They, as well as the NIH as a whole, are among the crown jewels of U.S.-funded science. Under this administration, these networks were at risk of extinction due to anti-science fanatics in high places. The networks can now survive to carry out more essential science which will bring us closer to the end of the HIV pandemic by improving our options for prevention and treatment. Congratulations to the activists and the researchers who worked so hard to make this renewal possible. Our work is not yet complete, and we will have to continue to pay close attention to ensuring that the next steps lead to successful renewal of full funding for all four HIV networks.” Mark Harrington, Executive Director, Treatment Action Group

“The clinical trials networks have been the backbone of HIV research in the United States and globally for decades. These networks have done more to advance our understanding of HIV and how to treat and prevent it, as well as advancing research in comorbidities and emerging pathogens. After months of unnecessary delays and relentless advocacy by researchers, advocates and communities calling for their release, the publication of these NOFOs is an important and long-overdue step forward. On initial read, these NOFOs are not ideal; it is notable that foreign sub-awards are not allowed, which is most unfortunate. It is a relief, though, that they are out.” Mitchell Warren, Executive Director, AVAC

“Let’s be clear; this victory would not have happened without the Save HIV Funding campaign and our partners. Even another week of delays could have irreversibly derailed the forthcoming submission and review processes, destabilizing and disrupting sophisticated scientific networks that have been at the forefront of innovative infectious disease research for decades. We are grateful to every stakeholder who has jumped into action on this issue– now we are committed to closely monitoring next steps and pushing back on ridiculous and dangerous changes to the NOFOs including disallowing foreign sub-awards.” Jeremiah Johnson, Executive Director, PrEP4All

“The release of the HIV Clinical Trials Network renewal notice while overdue was very welcome news. The networks have been an incredibly high-yield investment, facilitating public-private partnerships that continue to revolutionize the response to HIV and other infectious diseases – well beyond drug development. For their success to continue, it will be essential to ensure that partnerships with clinical trials sites outside of the United States can continue and, given the late release of the recompete notice – there must be mechanisms to prevent any disruptions in studies underway.” Andrea Weddle, Executive Director, HIV Medicine Association